NFKB1 and Parkinson disease: Many modulators have been found to reduce the inflammatory response and slow down the PD process by inhibiting the expression of NF-κB p65/p50, thereby suppressing the transcription of inflammatory genes and driving the polarization of microglial cells, prompting a conversion from a neurotoxic to a neuroprotective state [71].